Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-10-07

FDA Approved: JULUCA — Supplemental Application (ViiV Healthcare Company)

View source ↗

Summary

FDA approved a supplemental application for JULUCA (dolutegravir sodium and rilpivirine hydrochloride) from ViiV Healthcare Company.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Juluca (dolutegravir + rilpivirine)

Snippet

SUPPL AP for JULUCA (DOLUTEGRAVIR SODIUM AND RILPIVIRINE HYDROCHLORIDE)